Dr. Wingo on Surgical Approaches Across Gynecologic Malignancies

Shana Wingo, MD
Published: Tuesday, Apr 11, 2017



Shana Wingo, MD, gynecologic oncology, Arizona Oncology, discusses the various surgical approaches being explored and conducted across patients with gynecologic malignancies.

More surgical oncologists are doing minimally invasive surgery for patients with gynecologic malignancies, Wingo explains. However, this is more difficult for patients with ovarian cancer, she adds, as this is known to be a bulkier malignancy. The use of robotic surgery and minimally invasive surgery has been typically adopted and conducted for patients with uterine, cervical, and some early-stage ovarian cancers.

Additionally, in some centers with more experience with robotic surgeries, there are more aggressive procedures being done, she adds. Typically, a multi-port surgery is done in a laparotomy, but some centers are exploring single-site laparotomies. Time will tell if this single-site approach will be uniformly adopted across the United States, Wingo says.
 


Shana Wingo, MD, gynecologic oncology, Arizona Oncology, discusses the various surgical approaches being explored and conducted across patients with gynecologic malignancies.

More surgical oncologists are doing minimally invasive surgery for patients with gynecologic malignancies, Wingo explains. However, this is more difficult for patients with ovarian cancer, she adds, as this is known to be a bulkier malignancy. The use of robotic surgery and minimally invasive surgery has been typically adopted and conducted for patients with uterine, cervical, and some early-stage ovarian cancers.

Additionally, in some centers with more experience with robotic surgeries, there are more aggressive procedures being done, she adds. Typically, a multi-port surgery is done in a laparotomy, but some centers are exploring single-site laparotomies. Time will tell if this single-site approach will be uniformly adopted across the United States, Wingo says.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x